Molecular Subtype
Astrocytoma, IDH-Mutant
CI-CAN-00007241Explore in graph →
Non-malignant19 active trials
- NCIt
- C185167
Loading cancer entity…
Molecular Subtype
CI-CAN-00007241Explore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | recruiting | Phase 3 | 408 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | not yet recruiting | Phase 3 | 140 | Nuvation Bio Inc.INDUSTRY | 0 | Jul 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2026source: clinicaltrials